Beyond Transplantation: Cytomegalovirus Viremia as a Therapeutic Target in Non-Cytomegalovirus Syndromes

1

Cytomegalovirus (CMV) significantly impacts immunocompromised individuals, particularly in transplant recipients, affecting allograft function and survival.
2

A study found that CMV DNAemia in non-immunocompromised COVID-19 patients was linked to delayed recovery and increased mortality, especially in severe cases.
3

Preventing or treating CMV reactivation may improve outcomes in COVID-19, warranting further investigation into antiviral strategies for non-immunocompromised patients.
4

Trial designs for CMV prevention in non-transplant populations face challenges due to unclear impacts of CMV reactivation on clinical outcomes.
5

Future studies should explore CMV monitoring and treatment in non-immunocompromised patients, considering both mortality and clinically meaningful outcomes.

1